术后第1天引流淀粉酶与血清CRP联合评分预测临床相关胰瘘风险:90-1000评分
该前瞻性研究纳入2017至2019年274例胰腺切除患者,评估术后第1天引流淀粉酶和血清C反应蛋白(CRP)预测临床相关术后胰瘘(CR-POPF)的准确性。研究发现引流淀粉酶≥1000 UI/L和血清CRP≥90 mg/L为最佳截断值,二者组成的「90-1000」评分在预测CR-POPF方面显著优于术中胰腺实质特征,评分=0时在胰十二指肠切除术和远端胰腺切除术后的阴性预测值分别为97%和94%。
要点
- 术后第1天引流淀粉酶≥1000 UI/L和血清CRP≥90 mg/L是CR-POPF的独立预测因素。
- 「90-1000」评分=0时,胰十二指肠切除术后CR-POPF阴性预测值为97%,远端胰腺切除术后为94%。
- 该评分预测CR-POPF的准确性显著优于术中胰腺实质特征(P < .001)。
核心结论
- 基于术后第1天引流淀粉酶和血清CRP的联合评分能准确预测胰腺切除术后临床相关胰瘘风险。
研究设计与样本
- 前瞻性纳入2017至2019年接受胰腺切除术的患者274例,其中胰十二指肠切除术182例,远端胰腺切除术92例。
- 通过受试者工作特征曲线确定截断值,并用多因素logistic回归模型评估联合评分对临床相关术后胰瘘的预测价值。
主要发现
- 临床相关术后胰瘘发生率为21.2%(58例)。
- 胰腺腺体质地柔软者占47.8%(131例),主胰管直径≤3 mm者占55.8%(153例)。
- 引流淀粉酶≥1000 UI/L和血清CRP≥90 mg/L被确定为预测临床相关术后胰瘘的最佳截断值。
- 多因素分析显示,上述截断值在胰十二指肠切除术后(引流淀粉酶P < .001,血清CRP P = .006)和远端胰腺切除术后(引流淀粉酶P = .009,血清CRP P = .001)均为临床相关术后胰瘘的独立预测因素。
- 术后第1天「90-1000」评分在预测临床相关术后胰瘘方面显著优于术中胰腺实质特征(P < .001)。
关键数值与推荐
- 引流淀粉酶≥1000 UI/L和血清CRP≥90 mg/L为预测临床相关术后胰瘘的最佳截断值。
- 「90-1000」评分=0时,胰十二指肠切除术后临床相关术后胰瘘的阴性预测值为97%,远端胰腺切除术后为94%。
临床怎么用
- 术后第1天可检测引流淀粉酶和血清CRP,计算「90-1000」评分以评估临床相关术后胰瘘风险。
- 评分=0提示临床相关术后胰瘘风险极低,或可辅助早期安全拔管及调整围术期管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Several scoring systems predict risks of clinically relevant postoperative pancreatic fistula after pancreatectomy, but none have emerged as the gold standard. This study aimed to evaluate the accuracy of postoperative day 1 drain amylase and serum C-reactive protein levels in predicting clinically relevant postoperative pancreatic fistula compared with intraoperative pancreatic characteristics. METHODS: Patients who underwent pancreatectomy between 2017 and 2019 were included prospectively. Cutoff values were determined using receiver operating characteristic curves, and a score combining postoperative day 1 drain amylase and serum C-reactive protein was tested in a multivariate logistic regression model to evaluate clinically relevant postoperative pancreatic fistula risk. RESULTS: A total of 274 pancreatic resections (182 pancreaticoduodenectomies and 92 distal pancreatectomies) were included. The pancreatic gland texture was "soft" in 47.8% (n = 131), and 55.8% (n = 153) had a small size main pancreatic duct (≤3 mm). Clinically relevant postoperative pancreatic fistula occurred in 58 patients (21.2%). Drain amylase ≥1,000 UI/L and serum C-reactive protein ≥90 mg/L were identified as the optimal cutoffs to predict clinically relevant postoperative pancreatic fistula. On multivariate analysis these cutoffs were independent predictors of clinically relevant postoperative pancreatic fistula after both pancreaticoduodenectomies (drain amylase: P < .001, serum C-reactive protein: P = .006) and distal pancreatectomies (drain amylase: P = .009, serum C-reactive protein: P = .001). The postoperative day 1 "90-1000" model, a 2-value score relying on these cutoffs, significantly (P < .001) outperformed intraoperative pancreatic parenchymal characteristics in predicting clinically relevant postoperative pancreatic fistula after both pancreaticoduodenectomies and distal pancreatectomies. A postoperative day 1 "90-1000" score = 0 had a negative predictive value of 97% and 94%, respectively, after pancreaticoduodenectomy and distal pancreatectomies. CONCLUSION: A combined score relying on postoperative day 1 values of drain amylase and serum C-reactive protein levels was accurate in predicting risks of clinically relevant postoperative pancreatic fistula after pancreatectomy.
引用
- Guilbaud T, Garnier J, Girard E, et al. Postoperative day 1 combination of serum C-reactive protein and drain amylase values predicts risks of clinically relevant pancreatic fistula. The "90-1000" score. Surgery. 2021. PMID: 34092376. doi:10.1016/j.surg.2021.04.033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。